Briumvi (ublituximab-xiiy) and Ocrevus (ocrelizumab) are prescription drugs used to treat certain types of multiple sclerosis (MS). Both drugs are given as an intravenous (IV) infusion by a healthcare ...
Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq) is a prescription drug that’s used to treat certain forms of multiple sclerosis (MS). Ocrevus Zunovo comes as a ...
How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...
– Ocrevus data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS) – – Long-term safety ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus ® (ocrelizumab) and the investigational Bruton’s ...
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton kinase (BTK) inhibitor fenebrutinib, along with data ...
- MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis - - The ...
Ocrelizumab 920mg, hyaluronidase-ocsq 23000 Units; per 23mL; soln for SC inj; preservative-free. Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results